{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:36:30Z","timestamp":1793144190628,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"Importance<\/jats:title>Short-course antibiotic therapy could enhance adherence and reduce adverse drug effects and costs. However, based on sparse evidence, most guidelines recommend a longer course of antibiotics for nonsevere childhood community-acquired pneumonia (CAP).<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether a shorter course of antibiotics was noninferior to a longer course for childhood nonsevere CAP.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>MEDLINE, Embase, Web of Science, the Cochrane Library, and 3 Chinese databases from inception to March 31, 2022, as well as clinical trial registries and Google.com.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Randomized clinical trials comparing a shorter- vs longer-course therapy using the same oral antibiotic for children with nonsevere CAP were included.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Random-effects models were used to pool the data, which were analyzed from April 15, 2022, to May 15, 2022. Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to rate the quality of the evidence.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Treatment failure, defined by persistence of pneumonia or the new appearance of any general danger signs of CAP (eg, lethargy, unconsciousness, seizures, or inability to drink), elevated temperature (&amp;gt;38 \u00b0C) after completion of treatment, change of antibiotic, hospitalization, death, missing more than 3 study drug doses, loss to follow-up, or withdrawal of informed consent.<\/jats:p><\/jats:sec>Results<\/jats:title>Nine randomized clinical trials including 11\u202f143 participants were included in this meta-analysis. A total of 98% of the participants were aged 2 to 59 months, and 58% were male. Eight studies with 10\u202f662 patients reported treatment failure. Treatment failure occurred in 12.8% vs 12.6% of participants randomized to a shorter vs a longer course of antibiotics. High-quality evidence showed that a shorter course of oral antibiotic was noninferior to a longer course with respect to treatment failure for children with nonsevere CAP (risk ratio, 1.01; 95% CI, 0.92-1.11; risk difference, 0.00; 95% CI, \u20130.01 to 0.01; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%). A 3-day course of antibiotic treatment was noninferior to a 5-day course for the outcome of treatment failure (risk ratio, 1.01; 95% CI, 0.91-1.12; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%), and a 5-day course was noninferior to a 10-day course (risk ratio, 0.87; 95% CI, 0.50-1.53; I<\/jats:italic>2<\/jats:sup>\u2009=\u20090%). A shorter course of antibiotics was associated with fewer reports of gastroenteritis (risk ratio, 0.79; 95% CI, 0.66-0.95) and lower caregiver absenteeism (incident rate ratio, 0.74; 95% CI, 0.65-0.84).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this meta-analysis suggest that a shorter course of antibiotics was noninferior to a longer course in children aged 2 to 59 months with nonsevere CAP. Clinicians should consider prescribing a shorter course of antibiotics for the management of pediatric nonsevere CAP.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2022.4123","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:03:25Z","timestamp":1668441805000},"page":"1199","source":"Crossref","is-referenced-by-count":45,"title":["Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia"],"prefix":"10.1001","volume":"176","author":[{"given":"Qinyuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D.","family":"Florez","sequence":"additional","affiliation":[{"name":"School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Pediatrics, University of Antioquia, Medellin, Antioquia, Colombia"},{"name":"Pediatric Intensive Care Unit, Clinica Las Americas\u2013AUNA, Medellin, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Advanced Pediatrics Centre, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhan","family":"Shang","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enmei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"National Clinical Research Center for Child Health and Disorders, Chongqing, China"},{"name":"Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolong","family":"Chen","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"},{"name":"Chevidence Lab of Child and Adolescent Health, Children\u2019s Hospital of Chongqing Medical University, Chongqing, China"},{"name":"Research Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences (2021RU017), School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"},{"name":"Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China"},{"name":"Lanzhou University GRADE Centre, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9966","key":"poi220065r1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0140-6736(14)61698-6","article-title":"Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis.","volume":"385","author":"Liu","year":"2015","journal-title":"Lancet"},{"issue":"9859","key":"poi220065r2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"poi220065r3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMp1215093","article-title":"The future of antibiotics and resistance.","volume":"368","author":"Spellberg","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"poi220065r4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S2213-2600(18)30100-0","article-title":"Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life.","volume":"6","author":"Bui","year":"2018","journal-title":"Lancet Respir Med"},{"key":"poi220065r6","author":"Chee","year":"2022","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"poi220065r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months.","author":"Haider","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"poi220065r8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial.","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"17","key":"poi220065r9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1001\/jama.2021.17843","article-title":"Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial.","volume":"326","author":"Bielicki","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"poi220065r10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jamapediatrics.2020.6735","article-title":"Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial.","volume":"175","author":"Pernica","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"1","key":"poi220065r11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1912400","article-title":"Amoxicillin for 3 or 5 days for chest-indrawing pneumonia in Malawian children.","volume":"383","author":"Ginsburg","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"poi220065r12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/INF.0000000000000023","article-title":"Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial.","volume":"33","author":"Greenberg","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"poi220065r13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJMe2016328","article-title":"Antibiotics for childhood pneumonia\u2014do we really know how long to treat?","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"issue":"71","key":"poi220065r15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7443","key":"poi220065r16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/bmj.38049.490255.DE","article-title":"Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial.","volume":"328","author":"Agarwal","year":"2004","journal-title":"BMJ"},{"issue":"9336","key":"poi220065r18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0140-6736(02)09994-4","article-title":"Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial.","volume":"360","author":"Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) Pneumonia Study Group","year":"2002","journal-title":"Lancet"},{"key":"poi220065r19","first-page":"15","article-title":"A randomised, placebo controlled trial of short course cotrimoxazole for the treatment of pneumonia in Filipino children.","volume":"28","author":"Lupisan","year":"1999","journal-title":"Philipp J Microbiol Infect Dis"},{"issue":"7414","key":"poi220065r20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"poi220065r21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7650","key":"poi220065r22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"poi220065r23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/INF.0b013e3181cb45a7","article-title":"Lack of predictive value of tachypnea in the diagnosis of pneumonia in children.","volume":"29","author":"Shah","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"poi220065r24","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"poi220065r25","doi-asserted-by":"publisher","DOI":"10.7196\/AJTCCM.2020.v26i3.104","author":"Zar","year":"2020","journal-title":"Afr J Thorac Crit Care Med"},{"issue":"7","key":"poi220065r26","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/jac\/dku070","article-title":"Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial.","volume":"69","author":"Vilas-Boas","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"poi220065r27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1128\/AAC.47.3.997-1001.2003","article-title":"Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia.","volume":"47","author":"Fonseca","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"poi220065r28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"poi220065r29","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/jac\/dkw226","article-title":"Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.","volume":"71","author":"de Velde","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"9606","key":"poi220065r30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(08)60071-9","article-title":"Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial.","volume":"371","author":"Hazir","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"poi220065r31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/tmi.2011.16.issue-8","article-title":"Outpatient treatment of children with severe pneumonia with oral amoxicillin in four countries: the MASS study.","volume":"16","author":"Addo-Yobo","year":"2011","journal-title":"Trop Med Int Health"},{"issue":"8","key":"poi220065r32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/pch\/20.8.441","article-title":"Uncomplicated pneumonia in healthy Canadian children and youth: practice points for management.","volume":"20","author":"Le Saux","year":"2015","journal-title":"Paediatr Child Health"},{"issue":"1","key":"poi220065r33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/apa.13177","article-title":"Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children.","volume":"105","author":"Tapiainen","year":"2016","journal-title":"Acta Paediatr"},{"issue":"6","key":"poi220065r35","doi-asserted-by":"publisher","first-page":"439.e1","DOI":"10.1016\/j.anpedi.2014.10.028","volume":"83","author":"Moreno-P\u00e9rez","year":"2015","journal-title":"An Pediatr (Barc)"},{"key":"poi220065r36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41479-016-0006-x","article-title":"Antibiotics in childhood pneumonia: how long is long enough?","volume":"8","author":"Grimwood","year":"2016","journal-title":"Pneumonia (Nathan)"},{"key":"poi220065r37","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1093\/cid\/cix089","article-title":"Chest radiograph findings in childhood pneumonia cases from the multisite PERCH study.","volume":"64","author":"Fancourt","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"poi220065r38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3728","article-title":"Biomarkers and disease severity in children with community-acquired pneumonia.","volume":"145","author":"Florin","year":"2020","journal-title":"Pediatrics"},{"issue":"8","key":"poi220065r39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1473-3099(03)00721-7","article-title":"Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.","volume":"3","author":"Barlow","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"poi220065r34","author":"Lung","year":"2016"},{"key":"poi220065r5","unstructured":"World Health Organization. Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. Accessed May 17, 2022. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/137319\/9789241507813_eng.pdf"},{"key":"poi220065r14","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, . Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane Training. Accessed May 9, 2022. https:\/\/training.cochrane.org\/handbook\/current"},{"key":"poi220065r17","unstructured":"Kartasasmita? C, Saha? S; Short Course Cotrimoxazole Study Group. Consultative meeting to review evidence and research priorities in the management of acute respiratory infections (ARI). Accessed May 17, 2022. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/68635\/WHO_FCH_CAH_04.2.pdf?sequence=1"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2798514\/jamapediatrics_li_2022_oi_220065_1669653258.66805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:05:52Z","timestamp":1670256352000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2798514"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2022.4123","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}